**Case Study**

**EBV⁺ B-cell Lymphoproliferative Disorder Associated with Subsequent Development of Burkitt Lymphoma in a Patient with Idiopathic CD4⁺ T-lymphocytopenia**

Masaru Kojima,¹ Shinji Sakurai,² Yukio Morita,³ Naoya Nakamura,⁴ Shiro Sugihara,⁵ and Shun-ichi Shimano⁶

We report here a case of idiopathic CD4⁺ T-lymphocytopenia (ICL) associated with Epstein-Barr virus (EBV⁺) lymphoproliferative disorder (LPD) terminating in Burkitt lymphoma (BL). A 33-year-old Japanese male was admitted to the hospital showing severe CD4⁺ lymphocytopenia and neutropenia that was diagnosed as ICL in 1993. Twenty months after the onset of disease, right cervical lymphadenopathy was detected. Biopsy of the specimen showed reactive lymph node hyperplasia and interfollicular B-cell hyperplasia. Ninety-one months later, polypoid tumors were resected from the bilateral nasal cavities and were diagnosed as BL. Immunohistological studies suggested the reactive nature of the initial lymph node biopsy specimen. Polymerase chain reaction (PCR) analyses of immunoglobulin heavy-chain gene (IgH) demonstrated a polyclonal pattern in the initial lymph node lesion. However, the subsequent BL demonstrated a clonal band in the PCR assay for the IgH gene. As demonstrated in human immunodeficiency virus (HIV)-patients, clonal expansion of EBV infected B-cells in the initial lymph node lesion may progress to BL in this patient. The present case did not associate with severe opportunistic infections during the course of disease. EBV⁺ BL may be the first manifestation of severe immunodeficiency of the ICL in this patient. (J Clin Exp Hematopathol 48(2) : 55-59, 2008)

**Keywords:** CD4⁺ T-lymphocytopenia, Epstein-Barr virus, lymphoproliferative disorder, polymerase chain reaction

## INTRODUCTION

The Centers for Disease Control has applied the term idiopathic CD4⁺ lymphocytopenia (ICL) to describe rare patients in whom no detectable cause of low CD4⁺ T-cell counts can be found.¹⁻⁴ The criteria for diagnosing ICL requires < 300 × 10⁹/L CD4⁺ T-cells or a CD4⁺ T-cell count < 20% of total T-lymphocytes on two occasions, no evidence of human immunodeficiency virus (HIV) or -2, (HTLV)-1 or 2 infection, and no other cause of immunosuppression.¹⁻⁴ ICL appears to be a rare disorder. Patients with ICL may be asymptomatic, have a mildly idiopathic opportunistic infection such as herpes or candidiasis, or present with severe opportunistic infections such as cryptococcal meningitis, pneumocystis pneumonia, or tuberculosis. Many of these clinical findings are similar to the clinical presentation of HIV infections, but there is a difference. In HIV-infections, the risk of non-Hodgkin lymphoma is between 60 and 100 times the expected rate.⁵,⁶ Moreover, the majority of these cases demonstrated Epstein-Barr virus (EBV⁺) B-cell lymphomas.⁵,⁶ However, in the English literature, non-Hodgkin lymphomas have rarely been reported in ICL.⁷⁻¹² We present here a case of EBV⁺ lymphoproliferative disorder (LPD) associated with subsequent development of Burkitt lymphoma (BL) in a patient with ICL.

**CASE REPORT**

The clinical findings of this case have previously been presented in detail.¹³ A 33-year-old Japanese male was admitted to our hospital...
because severe neutropenia in July 1985. At that time, abnormal laboratory findings were a white blood cell count of 2.2 × 10⁹/L (neutrophils = 0.055 × 10⁹/L, CD4+ T-lymphocytes = 0.128 × 10⁹/L, and CD4/CD8 ratio = 0.1). Serum immunoglobulin levels were in the normal range. During the course of disease, repeated examinations of CD4+ T-lymphocyte counts demonstrated a count below 0.3 × 10⁹/L between 1985 and 1993 on five of nine examinations performed. Serological tests for HIV-1/2 and HTLV-1/2 were negative, and there were no risk factors for HIV infection. The etiology of neutropenia was unknown, and the neutropenia was sustained during the course of disease. The present case did not associate with severe opportunistic infection during the course of disease. In March 1991, he demonstrated EBV infection. At that time, abnormal serologic tests for EBV showed serological findings, suggesting reactivation of EBV infection. At that time, abnormal serologic tests for EBV showed serological findings, suggesting reactivation of EBV infection.

**MATERIALS AND METHODS**

Tissue specimens from lymph node biopsy and nasal tumors were fixed in formalin, routinely processed and embedded in paraffin. For light microscopic examination, the sections were stained with hematoxylin-eosin (HE).

Immunohistochemical studies were performed using the Ventana automated (BenchMarkTM) stainer according to the manufacturer’s instructions. A panel of antibodies included human immunoglobulin light chains (κ and λ) (Novocastra, Newcastle Upon Tyne, UK), PS-1 (CD3; Immunotech, Marseille, France), 4C7 (CD5; Novocastra), 56C6 (CD10; Novocastra), L26 (CD20; Dako A/S, Glostrup, Denmark), 124 (bcl-2; Dako), Ki-67 (MIB-1; Dako), CS.1-4 (latent membrane protein-1 [LMP-1]; Novocastra), and PE2 (EBV-encoded nuclear antigen-2 [EBNA2]; Novocastra). Sections with known reactivity for the antibodies assayed served as positive controls and the sections treated with normal rabbit- and mouse-serum served as negative controls.

*In situ* hybridization (ISH) with EBV-encoded small RNA (EBER) oligonucleotides was performed to test for the presence of EBV small RNA in the formalin-fixed paraffin-embedded sections using a Ventana automated (BenchMarkTM) stainer.

Paraffin-embedded tissues from the biopsy specimen were prepared for polymerase chain reaction (PCR), and rearranged immunoglobulin heavy-chain (IgH) genes were amplified using the seminested PCR method as described by Wan et al.¹⁵

Formalin-fixed, paraffin-embedded tissue was selected based on its pathology as determined by HE stain. To generate templates for PCR, we purified the DNA obtained from tissue using a commercial kit (DEXPAT, Takara, Tokyo, Japan). To identify EBV, we performed a comparative sequence analysis of the EBV genome.¹⁶ For genomic amplification, we used a set of previously reported primers: BAM-HIW forward primer (5’-CCC AAC ACT CCA CCA CAC C-3’) and the reverse primer (5’-TCT TAG GAG CTG TCC GAG GG-3’) (theoretical amplicon of 76 nt).¹⁶ The PCR reaction mixture contained 2 μL of template DNA, 1 μL of the BAM-HIW forward primer and reverse primers (20 pmol each), 12.5 μL of PCR Master Mix (Promega, Madison, WI), and 8.5 μL of distilled water free from DNase and RNase (total volume, 25 μL). The PCR protocol included incubation for 3 min at 95°C, followed by 35 cycles at 95°C for 30 sec, at 60°C for 30 sec, at 72°C for 45 sec, and an additional 5 min for elongation at 72°C after the last cycle. The sizes of the amplified DNA fragments were confirmed by electrophoresis on a 3.0% agarose gel. After purification of the DNA fragments with a QIAquick PCR purification kit (Qiagen GmbH, Hilden, Germany), the 76-bp nucleotide sequence, which included the target gene, was determined using an automated DNA sequencer (ABI 310 DNA sequencer, Applied Biosystems), and a Dye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems). Nucleotide sequences (37-bp) of the amplicon (76-bp) were analyzed genetically using the BLAST program (http://www.ddbj.nig.ac.jp/search/blast-e.html) provided by the DNA Data Bank of Japan (DDBJ) home page.

**RESULTS**

**Pathological, immunohistochemical and ISH findings**

Lymph node biopsy specimen

On low power field, the lesion was characterized by numerous enlarged, bizarre-shaped coalescing lymphoid follicles with distortion rather than effacement of the lymph node architecture (Fig. 1a). The paracortical area and lymphoid sinus were compressed by enlarged follicles. However, tingible-body macrophages were numerous and polarization was seen in the lymphoid follicles. Various numbers of germinal centers had undergone follicular lysis. Monocytoid B-lymphocyte foci were observed located next to blood vessels and sinuses.

Immunohistochemical study demonstrated that lymphoid follicles and monocytoid B-lymphocyte were positive for CD20. Staining with CD20, CD3, and CD5 showed a mixed
Idiopathic CD4+ T lymphocytopenia

Fig. 1. (1a) Low power field of the initial lymph node biopsy specimen. The lesion was characterized by numerous enlarged, atypically-shaped coalescing lymphoid follicles with distortion rather than effacement of the lymph node architecture. HE, x10. (1b) Approximately 100 EBER-positive cells had small-to-large nuclei and were located both in the interfollicular area and in the lymphoid follicles. EBER, x10. (1c) High-power field of the nasal tumor. Medium-sized cells showed a monotonous proliferation accompanied by a starry-sky appearance. The tumor cells had round nuclei with multiple basophilic small nucleoli and intensely basophilic cytoplasm. HE, x100. (1d) Immunohistochemistry. Nearly 100% of the tumor cells were Ki-67+. x100. (1e) ISH. Note the numerous EBER+ cells. x100. (1f) PCR analysis for clonal immunoglobulin heavy chain rearrangement. The lanes contain molecular-weight markers, negative control (N), polyclonal control (P), Burkitt lymphoma (BL), and initial lymph node biopsy (RFH).
nature of the small- and medium-sized lymphocytes, and immunoblasts in the interfollicular area. B-cells in the germinal centers and a nest of MBLs were both bcl-2 negative, while bcl-2 positivity was expressed in mantle zone B-cells.\textsuperscript{17} CD10\textsuperscript{+} large lymphoid cells were confined strictly to the germinal centers. Immunohistochemical studies of light chain determinants for germinal center and MBLs demonstrated a polyclonal pattern.\textsuperscript{17} There were no LMP-1\textsuperscript{+}, EBNA-2\textsuperscript{+} cells in the lesion.

Approximately 100 EBER-positive cells had small to large nuclei and were located both in the interfollicular area and in the lymphoid follicles (Fig. 1b).

**Nasal tumor**

Histologically, the medium-sized cells from the nasal tumor showed monotonous proliferation accompanied by numerous mitoses and apoptotic bodies (starry-sky appearance) (Fig. 1c). The tumor cells had round nuclei with multiple basophilic small sized nucleoli and deeply basophilic cytoplasm.

Immunohistochemical studies demonstrated that tumor cells were CD3\textsuperscript{-}, CD5\textsuperscript{-}, CD10\textsuperscript{+}, CD20\textsuperscript{+}, bcl-2\textsuperscript{-}, and cytoplasmic immunoglobulin\textsuperscript{-}. Nearly 100\% of the tumor cells were Ki-67\textsuperscript{+} (Fig. 1d). The results of LMP-1 and EBNA-2 expression were not evaluated.

ISH study demonstrated that numerous EBER\textsuperscript{+} tumor cells (Fig. 1e). Histological, immunohistochemical and EBV findings of the nasal tumor were compatible with BL.\textsuperscript{19} The initial lymph node biopsy specimen from this case showed florid follicular and interfollicular B-cell hyperplasia. ISH studies demonstrated approximately 100 EBER\textsuperscript{+} lymphocytes in both the interfollicular area and lymphoid follicles. Immunohistological studies suggested the reactive nature of the initial lymph node biopsy specimen. PCR analyses for IgH genes demonstrated a polyclonal pattern in the initial lymph node lesion. However, the subsequent BL demonstrated clonal band in the PCR assay for the IgH gene. PCR analyses for EBV-genomes demonstrated the same single clonal infection of EBV in the initial lymph node lesion and the second nasal tumor. As Shibata \textit{et al.} demonstrated in an HIV-patient, clonal expansion of EBV infected B-cells in the initial lymph node lesion in this patient may progress to BL in this patient.\textsuperscript{19} However, PCR analysis for clonal EBV infection was not performed in this case.

A number of observations suggest that clinical distinctions exist among AIDS-related B-cell lymphomas according to their histopathological findings. AIDS-related BL may develop in the presence of relatively sustained peripheral blood CD4\textsuperscript{+} T-cell levels and may be the first manifestation of AIDS in a significant fraction of cases.\textsuperscript{20-22} On the other hand, AIDS-related diffuse large B-cell lymphoma tends to develop in the presence of low CD4 counts and is frequently a late manifestation of AIDS. The present case did not associate with severe opportunistic infection during the course of disease. EBV\textsuperscript{+} BL may be the first manifestation of severe immunodeficiency of the ICL in this patient. However, at the onset of BL, peripheral blood CD4\textsuperscript{+} T-cell count was not examined. Moreover, EBV\textsuperscript{+} AIDS-related BL fail to express EBV transforming antigen EBNA-2 and LMP-1.\textsuperscript{21,22} The tumor cells of the present case also EBNA-2\textsuperscript{-} and LMP-1\textsuperscript{-}.

The present case indicates that EBV\textsuperscript{+} B-cell lymphomas occur in patients with ICL as well as in AIDS patients.
REFERENCES


